Literature DB >> 32613782

Response: Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J 2020;44:267-76).

Hokyou Lee1,2, Gyuri Kim3, Yong Ho Lee1,4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32613782      PMCID: PMC7332324          DOI: 10.4093/dmj.2020.0127

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
We would like to thank Dr. Yu for showing great interest in and providing insightful comments on our article, entitled “Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus,” which was published in Diabetes & Metabolism Journal [1]. In our study, we observed a smaller odds ratio with significant heterogeneity for left ventricular (LV) diastolic dysfunction associated with nonalcoholic fatty liver disease (NAFLD) or liver fibrosis in the presence of insulin resistance. This is a form of a negative multiplicative interaction between insulin resistance and hepatic steatosis/fibrosis in association with LV diastolic dysfunction [2]. The direction of the additive interaction, although not statistically significant, was also consistent with a negative interaction. Therefore, competing antagonism may exist between insulin resistance and hepatic steatosis/fibrosis, which share several common biological mechanisms and may compete with regard to outcomes [34]. The clinical implications of our study suggest that the presence of hepatic steatosis or fibrosis may be a “red flag” for subclinical cardiac dysfunction and diabetic cardiomyopathy among type 2 diabetes mellitus patients without severe systemic insulin resistance or other overt cardiometabolic diseases, seemingly low-risk patients. We agree with Dr. Yu that long-term exposure to high blood pressure is an important risk factor for LV dysfunction and remodeling [5]. Although there is limited evidence on the association between the duration of hypertension and NAFLD or liver fibrosis, it may be reasonable for future studies to include the duration of hypertension as a potential confounder. We also agree that randomized controlled trials should evaluate the beneficial effects of NAFLD intervention on LV diastolic dysfunction and remodeling. Prospective cohort studies as well as animal studies should seek to establish the underlying mechanisms and causality between NAFLD and diastolic dysfunction in type 2 diabetes mellitus. We are again grateful for Dr. Yu's invaluable comments.
  5 in total

1.  Remarks on antagonism.

Authors:  Tyler J VanderWeele; Mirjam J Knol
Journal:  Am J Epidemiol       Date:  2011-04-13       Impact factor: 4.897

Review 2.  Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

Authors:  Briohny W Smith; Leon A Adams
Journal:  Nat Rev Endocrinol       Date:  2011-05-10       Impact factor: 43.330

3.  Cumulative Blood Pressure in Early Adulthood and Cardiac Dysfunction in Middle Age: The CARDIA Study.

Authors:  Satoru Kishi; Gisela Teixido-Tura; Hongyan Ning; Bharath Ambale Venkatesh; Colin Wu; Andre Almeida; Eui-Young Choi; Ola Gjesdal; David R Jacobs; Pamela J Schreiner; Samuel S Gidding; Kiang Liu; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2015-06-30       Impact factor: 24.094

4.  The Interaction Continuum.

Authors:  Tyler J VanderWeele
Journal:  Epidemiology       Date:  2019-09       Impact factor: 4.822

5.  Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Hokyou Lee; Gyuri Kim; Young Ju Choi; Byung Wook Huh; Byung Wan Lee; Eun Seok Kang; Bong Soo Cha; Eun Jig Lee; Yong Ho Lee; Kap Bum Huh
Journal:  Diabetes Metab J       Date:  2019-02-28       Impact factor: 5.376

  5 in total
  1 in total

1.  Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.

Authors:  Dandan Peng; Zhenqiu Yu; Mingwei Wang; Junping Shi; Lei Sun; Yuanyuan Zhang; Wenbin Zhao; Chen Chen; Jiake Tang; Chunyi Wang; Jie Ni; Wen Wen; Jingjie Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.